Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy | Journal of the American Heart Association

BackgroundCardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life. In this review, we …

Read the full article here

Related Articles

| AHA/ASA Journals

Circulation: Cardiovascular Imaging welcomes authors whose presentations have been accepted at the upcoming 2025 European Society of Cardiology (ESC) Congress to submit their manuscripts for…

| AHA/ASA Journals

Circulation: Cardiovascular Imaging welcomes authors whose presentations have been accepted at the upcoming 2025 European Society of Cardiology (ESC) Congress to submit their manuscripts for…